Category Archives: C. diff. Spores and More Global Broadcasting Network

C. diff. Radio

C. diff. Spores and More (cdiffradio.com) Launches Season III

cdiffRadioLogoMarch2015

 

 

 

 

 

Welcome to Season III of C. diff. Spores and More Global Broadcasting Network, and sponsored by Clorox Healthcare (www.cloroxhealthcare.com/cdiffradio)

Join us every Tuesday at 10:00 a.ml PT / 11:00 a.m. MT / 12:00 p.m. CT / 1:00 p.m. ET for our live broadcast.

Dr. Katherine Fleming-Dutra, MD is a medical epidemiologist with the Office of Antibiotic Stewardship in the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention (CDC).  Dr. Fleming-Dutra is a Pediatrician and Pediatric Emergency Medicine physician and has focused on infectious diseases, epidemiology, and antibiotic stewardship in the outpatient setting in her career at the CDC.

Dr. Fleming-Dutra spent an hour with us discussing the Over Prescribing Of Antibiotics   —  and the Key to Fighting Antibiotic-Resistance — clinicians and patients.

https://www.voiceamerica.com/episode/96728/a-prescription-for-over-prescribing-the-key-to-fighting-antibiotic-resistance

The guidelines, programs, campaigns, tracking methods, and tools being provided by the CDC are outstanding and need to be shared and implemented by clinicians to continue reducing the rate by 50% by 2020 of all inappropriate selections and incorrect duration in antibiotic therapies.  Antibiotic Stewardship programs are available and should be in place across the healthcare industry.

Antibiotic Stewardship Guidelines

For Healthcare Providers and Professionals:  To learn more about the outstanding tools provided by the CDC  to aid in bringing about positive changes please click on the links provided below:

Here are links to the Core Elements:

https://www.cdc.gov/getsmart/community/improving-prescribing/core-elements/core-outpatient-stewardship.html

https://www.cdc.gov/getsmart/healthcare/implementation/core-elements.html

https://www.cdc.gov/longtermcare/prevention/antibiotic-stewardship.html

 AND

Links to Patient Safety Atlas

Antibiotic Resistance Patient Safety Atlas: Outpatient Antibiotic Prescriptions by State Data (2011-2014)

Antibiotic Resistance Patient Safety Atlas: Healthcare Facilities Reporting HAIs by State Data (2011-2014)

https://www.voiceamerica.com/episode/96728/a-prescription-for-over-prescribing-the-key-to-fighting-antibiotic-resistance

We know that the CDC’s most recent figure for C. difficile-associated deaths in the U.S. is considerably higher than that of any previous survey. According to the CDC*

  • Nearly 500,000 patients are diagnosed with a C. diff infection estimated per year in the U.S., with more than 29,000 deaths
  • Up to $4.8 billion in excess health care costs for acute care facilities
  • Prevention steps include antibiotic stewardship and improved infection control in hospitals, doctor’s offices, nursing homes and other healthcare facilities

C. diff. Spores and More ™“ spotlights world renowned topic experts, research scientists, healthcare professionals, organization representatives, C. diff. survivors, board members, and their volunteers who are all creating positive changes in the
C. diff.
community and worldwide.

Through interviews – each episode becomes part of the living library.  The podcasts are accessed continuously promoting education and advocating the C Diff Foundation’s mission that are connecting, educating, and empowering listeners worldwide.

Questions received through the show page portal will be reviewed and addressed  by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP,  Dr. Fred Zar is a Professor of Clinical Medicine, Vice HeZarPhotoWebsiteTop (2)ad for Education in the Department of Medicine, and Program Director of the Internal Medicine Residency at the University of Illinois at Chicago.  Over the last two decades he has been a pioneer in the study of the treatment of Clostridium difficile disease and the need to stratify patients by disease severity.

Take our program on the go…………..download a mobile app today

www.voiceamerica.com/company/mobileapps

healthwellnesshealth (2)

 

 

 

 

Thanks and Appreciation To Our Guests For Joining Us On C. diff. Spores And More Season II

ThankYouInkPen

As Season II concludes, we wish to take this opportunity to sincerely thank each
and every guest for taking time out of their
busy schedule and joining us on Tuesday’s at
10:00a Pacific Time / 1:00p Eastern Time over the past seven months.

C. diff. Spores and More Global Broadcasting Network will be taking a break and will return to live broadcasting on  January 17th, 2017 with the Centers for Disease Control and Prevention (CDC) leading the way with our guest
Dr. Katherine Fleming-Dutra, Medical Officer, CDC’s Office of Antibiotic Stewardship.

A Prescription for Over-Prescribing: The Key to Fighting
Antibiotic Resistance

Dr. Fleming-Dutra is a medical epidemiologist with the Office of Antibiotic Stewardship in the Division of Healthcare Quality Promotion at the Centers Disease Control and Prevention (CDC).

Dr. Fleming-Dutra is a pediatrician and pediatric emergency medicine physician and has focused on infectious diseases epidemiology and antibiotic stewardship in the outpatient setting in her career at CDC.

Join Dr. Fleming-Dutra as she discusses a recent study published by the Journal of the American Medical Association, was released showing that at least 30 percent of all prescriptions written in doctors’ offices and emergency rooms are completely unnecessary. So how do we use these alarming results to transform the culture of over-prescribing Dr. Katherine Fleming-Dutra, M.D., will:

  • Give a detailed explanation of the study results, and provide an in-depth review of specific findings;
  • Highlight what CDC is doing to promote antibiotic stewardship across healthcare settings, and
  • Identify what clinicians, other health care professionals, and patients can do to improve antibiotic prescribing, therefore fighting antibiotic resistance.

 

C diff Radio™ Live Broadcast AND Podcasts

cdiffRadioLogoMarch2015C. diff. Spores and More Global Broadcasting Network™

  brought to you by VoiceAmerica and
sponsored by Clorox Healthcare

An educational program that is dedicated to  C. difficile Infections  and more–

 

Click On The LOGO  Above And Enjoy Listening To the Live Broadcasts In the C. diff. Spores and More Podcast Library.

 

Live Broadcast airs
on Tuesdays at:    10a PT,    11a MT,   12p CT,    1p ET

We are pleased to share  “C. diff. Spores and More ™”  with you because, as advocates of  C. diff.,  we know the importance of this cutting-edge new weekly radio show  and what it means for our Foundation’s community worldwide.–

Hard Facts: Deaths and illnesses are much higher than reports have shown. Nearly half a million Americans suffered from Clostridium difficile (C. diff.) infections in a single year according to a study released today, February 25, 2015, by the Centers for Disease Control and Prevention (CDC).

• More than 100,000 of these infections developed among residents of U.S. nursing homes.

Approximately 29,000 patients died within 30 days of the initial diagnosis of a C. diff. infection. Of these 29,000 – 15,000 deaths were estimated to be directly related to a
C. diff. infection. Therefore; C. diff. is an important cause of infectious disease death in the U.S.

♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦
Previous studies indicate that C. diff. has become the most common microbial cause of Healthcare-Associated Infections found in U.S. hospitals driving up costs to $4.8 billion each year in excess health care costs in acute care facilities alone. Approximately
two-thirds of C. diff. infections were found to be associated with an inpatient stay in a health care facility, only 24% of the total cases occurred in patients while they were hospitalized. The study also revealed that almost as many cases occurred in nursing homes as in hospitals and the remainder of individuals acquired the
Healthcare-Associated infection, C. diff., recently discharged from a health care facility.

This new study finds that 1 out of every 5 patients with the Healthcare-Associated Infection (HAI), C. diff., experience a recurrence of the infection and 1 out of every 9 patients over the age of 65 diagnosed with a HAI – C. diff. infection died within 30 days of being diagnosed. Older Americans are quite vulnerable to this life-threatening diarrhea infection. The CDC study also found that women and Caucasian individuals are at an increased risk of acquiring a C. diff. infection. The CDC Director, Dr. Tom Frieden, MD, MPH said, “C. difficile infections cause immense suffering and death for thousands of Americans each year.” “These infections can be prevented by improving antibiotic prescribing and by improving infection control in the health care system. CDC hopes to ramp up prevention of this deadly infection by supporting State Antibiotic Resistance Prevention Programs in all 50 states.”

“This does not include the number of C. diff. infections taking place and being treated in other countries.”  “The  C Diff Foundation supports hundreds of communities by sharing the Foundation’s mission and  raising C. diff. awareness to healthcare professionals, individuals, patients, families,  and communities working towards a shared goal ~  witnessing a reduction of newly diagnosed C. diff. cases by 2020 .”   ” The C Diff Foundation volunteer Advocates are greatly appreciated and continue to create positive changes by sharing their time  aiding in the success of our mission “Raising C. diff. awareness ™”  worldwide.

C. diff. Spores and More ™“ spotlights world renowned topic experts, research scientists, healthcare professionals, organization representatives, C. diff. survivors, board members, and their volunteers who are all creating positive changes in the
C. diff.
community and more.

Through their interviews, the C Diff Foundation mission will connect, educate, and empower listeners worldwide.

Questions received through the show page portal will be reviewed and addressed  by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP,  Dr. Fred Zar is a Professor of Clinical Medicine, Vice HeZarPhotoWebsiteTop (2)ad for Education in the Department of Medicine, and Program Director of the Internal Medicine Residency at the University of Illinois at Chicago.  Over the last two decades he has been a pioneer in the study of the treatment of Clostridium difficile disease and the need to stratify patients by disease severity.

 

Take our show on the go…………..download a mobile app today

www.voiceamerica.com/company/mobileapps

healthwellnesshealth (2)

 

CloroxHealthcare_72

Programming for C. diff. Spores and More ™ is made possible through our official Corporate Sponsor;  Clorox Healthcare

We look forward to sharing time with our worldwide listeners when we return in January, Season III. 

Until then………………

We send out get-well wishes to everyone being treated for and recovering from a C. difficile infection and all wellness draining illnesses worldwide.

“None of us can do this alone – All of us can do this together!”

July 19th Join C. diff. Spores and More With Dr. Matthew Henn – Discussing The Role Of the Microbiome In Health and Disease: The Basics

 

Listen To the Live Broadcast

On  July 19th,  2016

cdiffRadioLogoMarch2015CLICK ON THE LOGO TO BE REDIRECTED TO LISTEN TO THE BROADCAST

Listen in to the live broadcast at 10a PT,   11a MT,   12p CT,   1p ET     6p UK


C. diff. Spores and More,”™ Global Broadcasting Network – innovative and educational interactive healthcare talk radio program discusses

This Episode:  

The Role of the Microbiome in Health and Disease: The Basics

With Our Guest

Dr. Matthew Henn,  Senior Vice President, Head of Drug Discovery and Bioinformatics

Matthew Henn is the Senior Vice President and Head of Drug Discovery & Bioinformatics of Seres Therapeutics, Inc. He has more than 16 years of combined research experience in microbial ecology, genomics, and bioinformatics that spans both environmental and infectious disease applications.

Dr. Henn’s research has focused on the development, implementation, and application of genomic technologies in the area of microbial populations and their metabolic functions. Prior to joining Seres, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard.

Join us on Tuesday, July 19th as Dr. Henn provides the foundation educational information about the microbiome by answering the fundamental questions of what is it, why is it important, how does it impact patients with C. difficile infections, and what are the possibilities of the microbiome as a therapeutic target for future drugs.  This interview will solely be with Dr. Matthew Henn, Senior Vice President and Head of Drug Discovery & Bioinformatics at Seres Therapeutics, Inc,.

Seres Therapeutics is a leading microbiome therapeutics company dedicated to creating a new class of medicines to treat diseases resulting from imbalances in the microbiome.  These first-in-class drugs, called Ecobiotics®, are ecological compositions of beneficial organisms that are designed to restore a healthy human microbiome. The discovery efforts at Seres Therapeutics currently span metabolic, inflammatory, and infectious diseases.

♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦

C. diff. Spores and More ™“ Global Broadcasting Network spotlights world renowned topic experts, research scientists, healthcare professionals, organization representatives,C. diff. survivors, board members, and C Diff Foundation volunteers who are all creating positive changes in the C. diff. community worldwide.

Through their interviews, the C Diff Foundation mission will connect, educate, and empower many worldwide.

Questions received through the show page portal will be reviewed and addressed  by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP,  Dr. Fred Zar is a Professor of Clinical Medicine, Vice HeZarPhotoWebsiteTop (2)ad for Education in the Department of Medicine, and Program Director of the Internal Medicine Residency at the University of Illinois at Chicago.  Over the last two decades he has been a pioneer in the study of the treatment of
Clostridium difficile disease and the need to stratify patients by disease severity.

To access the C. diff. Spores and More program page and library, please click on the following link:    www.voiceamerica.com/show/2441/c-diff-spores-and-more

Take our show on the go…………..download a mobile app today

http://www.voiceamerica.com/company/mobileapps

Programming for C. diff. Spores and More ™  is made possible through our official  Sponsor;  Clorox Healthcare

CloroxHealthcare_72

July 5th Join C. diff. Spores and More With Dr. Garey and Dr. Vickers As We Discuss Summit Therapeutics: Ridinilazole, a Microbiome Preserving Antibiotic For the Treatment Of C. difficile Infection (CDI)

 

Listen to the live broadcast

on  July 5th,  2016

cdiffRadioLogoMarch2015CLICK ON THE LOGO TO BE REDIRECTED TO THE  LIVE BROADCAST PAGE

Listen in to the live broadcast at 10a PT,   11a MT,   12p CT,   1p ET     6p UK


C. diff. Spores and More,”™ Global Broadcasting Network – innovative and educational interactive healthcare talk radio program discusses

This Episode:  

Summit Therapeutics: ridinilazole, a microbiome preserving antibiotic for the treatment of a C. difficile infection (CDI)

With Our Guests:

Dr. Kevin W. Garey; Chair, Department of Pharmacy Practice and Translational Research Professor of Pharmacy Practice at the University of Houston College of Pharmacy, Houston, TX

Dr. Richard Vickers, Chief Scientific Officer at Summit Therapeutics

Join us as we discuss a promising and new treatment for a C. difficile infection.  Summit Therapeutic’s Ridinilazole, a microbiome preserving antibiotic will be introduced with updates with our  guests Dr. Kevin W. Garey, Chair, Department of Pharmacy Practice and Translational Research, Professor of Pharmacy Practice at the University of Houston College of Pharmacy, Houston, Texas and  Dr. Richard Vickers, Chief Scientific Officer at Summit Therapeutics

♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦

C. diff. Spores and More ™“ Global Broadcasting Network spotlights world renowned topic experts, research scientists, healthcare professionals, organization representatives,C. diff. survivors, board members, and C Diff Foundation volunteers who are all creating positive changes in the C. diff. community worldwide.

Through their interviews, the C Diff Foundation mission will connect, educate, and empower many worldwide.

Questions received through the show page portal will be reviewed and addressed  by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP,  Dr. Fred Zar is a Professor of Clinical Medicine, Vice HeZarPhotoWebsiteTop (2)ad for Education in the Department of Medicine, and Program Director of the Internal Medicine Residency at the University of Illinois at Chicago.  Over the last two decades he has been a pioneer in the study of the treatment of
Clostridium difficile disease and the need to stratify patients by disease severity.

To access the C. diff. Spores and More program page and library, please click on the following link:    www.voiceamerica.com/show/2441/c-diff-spores-and-more

Take our show on the go…………..download a mobile app today

http://www.voiceamerica.com/company/mobileapps

Programming for C. diff. Spores and More ™  is made possible through our official  Sponsor;  Clorox Healthcare

CloroxHealthcare_72

PODCAST of June 28th C. diff. Spores and More With Guests Dr. Sliman & Dr. Pimentel As We Discuss Synthetic Biologics: Protecting the Gut Microbiome and Maintaining Human Health

 

Listen to the PODCAST of the live broadcasted

on  June 28th,  2016

cdiffRadioLogoMarch2015CLICK ON THE LOGO TO BE REDIRECTED TO THE PODCAST OF THE LIVE BROADCAST

Listen in to the live broadcast at 10a PT,   11a MT,   12p CT,   1p ET


C. diff. Spores and More,”™ Global Broadcasting Network – innovative and educational interactive healthcare talk radio program discusses

This Episode:  

Synthetic Biologics: Protecting the Gut Microbiome
and Maintaining Human Health

With Our Guests:

Dr. Joseph Sliman, MD
Senior Vice President, Clinical & Regulatory Affairs

Dr. Mark Pimentel, MD, FRCP(C)
Director of the GI Motility Program and Laboratory at Cedars-Sanai

On Tuesday, June 28th  we discussed public awareness of the microbiome and its link to human health – is on the rise as evidenced by recent government-sponsored programs such as the National Microbiome Initiative.  Protection of the natural gut microbiome from the unintended consequences of intravenous (IV) antibiotics, which are excreted into the gut, is expected to protect against opportunistic enteric infections.   Recent clinical data suggest that the absence or abundance of certain microbes may be directly linked to certain infections and diseases including a Clostridium difficile infection (CDI), and irritable bowel syndrome (IBS).   Synthetic Biologics is developing two microbiome-focused drug candidates in Phase 2 development including SYN-004 which is designed to protect the gut microbiome by degrading certain IV beta-lactam antibiotics for the prevention of a CDI, antibiotic associated-diarrhea (AAD) and the emergence of antibiotic-resistant organisms.  And SYN-010 is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).   Synthetic Biologics Inc.’s Joseph Sliman, MD, Senior Vice President, Clinical and Regulatory Affairs with Mark Pimentel, MD, FRCP(C), Director of the GI Motility Program and Laboratory at Cedars-Sinai, will be discussing both the Company’s novel microbiome-focused product candidates.

 

MORE ABOUT OUR GUESTS:

Dr Joseph Sliman, MD, Senior Vice President, Clinical and Regulatory Affairs.

Dr. Sliman joined Synthetic Biologics in January 2013 as the Senior Vice President, Clinical & Regulatory Affairs. In this position, Dr. Sliman will be responsible for the design and implementation of all aspects of clinical development, including clinical trials, and will lead the Company’s regulatory initiatives. During his service in the United States Navy, Dr. Sliman led the U. S. Pacific Fleet disease surveillance programs, including influenza surveillance, preparedness, and prevention, as well as communicable disease and injury surveillance and prevention and health policy development. Dr. Sliman earned an M.D. from the Uniformed Services University, a Master’s Degree in Public Health from the Johns Hopkins University School of Public Health, and a B.S. in Molecular and Cell Biology, with Honors in Biology, from Pennsylvania State University

Dr Mark Pimental, MD, FRCP(C), Director of the GI Motility Program and
Laboratory at Cedars-Sanai.

Mark Pimentel, MD, FRCP(C), is Director of the GI Motility Program and
Laboratory at Cedars-Sinai, Associate Professor of Medicine at CSMC and Professor of Medicine at UCLA Geffen School of Medicine in Los Angeles, CA. Dr. Pimentel completed three years of undergraduate degree with honors in microbiology and biochemistry at the University of Manitoba, Canada. This was followed by his medical degree and his BSc(Med) from the Univeristy of Manitoba Health Sciences Center in Winnipeg, Manitoba, Canada where he also completed a residency in internal medicine. His medical training includes a fellowship in gastroenterology at the UCLA Affiliated Training Program. Active in research Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic sciences, transitional, and clinical studies in such areas as IBS, and the relationship between gut flora composition and human disease.

♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦

C. diff. Spores and More ™“ Global Broadcasting Network spotlights world renowned topic experts, research scientists, healthcare professionals, organization representatives,C. diff. survivors, board members, and C Diff Foundation volunteers who are all creating positive changes in the C. diff. community worldwide.

Through their interviews, the C Diff Foundation mission will connect, educate, and empower many worldwide.

Questions received through the show page portal will be reviewed and addressed  by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP,  Dr. Fred Zar is a Professor of Clinical Medicine, Vice HeZarPhotoWebsiteTop (2)ad for Education in the Department of Medicine, and Program Director of the Internal Medicine Residency at the University of Illinois at Chicago.  Over the last two decades he has been a pioneer in the study of the treatment of
Clostridium difficile disease and the need to stratify patients by disease severity.

To access the C. diff. Spores and More program page and library, please click on the following link:    www.voiceamerica.com/show/2441/c-diff-spores-and-more

 

Take our show on the go…………..download a mobile app today

http://www.voiceamerica.com/company/mobileapps

Programming for C. diff. Spores and More ™  is made possible through our official  Sponsor;  Clorox Healthcare

CloroxHealthcare_72

June 21st Join C. diff. Spores and More #CdiffRadio Discuss the Partnership Between Laboratories and Clinical Staff For Accurate C. diff. Infection Diagnosis

 

Listen to the live broadcast from  June 21st,  2016

cdiffRadioLogoMarch2015


To access the live broadcast and Podcast Library
C. diff. Spores and More  Global Broadcasting Network
please click on the logo above *

C. diff. Spores and More,” Global Broadcasting Network – innovative and educational interactive healthcare talk radio program discusses

This Episode:   The Partnership Between Laboratories and Clinical Staff For the Accurate Diagnosis of a C. difficile Infection.

With Our Guests:  Dr. Steven Cagas, Ph.D.,  Dr. Nathan A. Ledeboer, Ph.D, D(ABMM),
Dr. Whitney R. Buckel, PharmD, BCPS, And  Jeanine Thomas

 

Learn about the importance of laboratory testing in the identification of C. difficile Infections (CDI). We will open with an interview with Jeanine Thomas, President and Founder of the MRSA Survivors Network who is a survivor of both MRSA and C. diff. infections. She will share her healthcare journey including the role that diagnostics played. Our second guest will be Nathan A. Ledeboer, PhD, D(ABMM), Medical Director of Microbiology and Molecular Diagnostics for Wisconsin Diagnostic Laboratories and Froedtert Health. He will give an overview and comparisons between various testing technologies available to clinical laboratories today. Our third guest will be Whitney R. Buckel, PharmD, BCPS who is the Infectious Diseases and Antimicrobial Stewardship Clinical Pharmacist at Intermountain Medical Center. Whitney will share with us some important details of how nurses and doctors can support the lab by taking into account the full clinical picture before sending specimens to the lab. Our last guest, Dr. Steven Cagas, will give us a brief overview of Roche Diagnostics as well as their new cobas® Cdiff Test.

 

MORE ABOUT OUR GUESTS:

Jeanine Thomas – President/ Founder of MRSA Survivors Network, National Spokesperson for MRSA, MRSA Expert and Consultant     Ms. Thomas founded MRSA Survivors Network in early 2003 due to having been critically ill with a MRSA infection, sepsis and C. difficile. Her organization was the first in the U.S. to raise the alarm about the MRSA epidemic, healthcare-acquired infections (HAI’s) and antibiotic resistance (AMR) to state and federal health officials in the U.S.   Ms. Thomas has been designated a “Patient Safety Champion” with the World Health Organizations’ World Alliance for Patient Safety (2008 – present), past member of the Joint Commission’s Patient and Family Advisory Council (2008-2010), FDA- appointed consultant on the FDA Anti-Infective Drug Advisory Committee (2008 –present) and a member of Brookings Institution’s Antibiotic Drug Development and Antimicrobial Stewardship Council (2012 –present). WHO- appointed patient representative on developing their Hand Hygiene and Antimicrobial-resistance programs for patients (2009-2012). She is a member of the Patient, Consumer and Public Health Coalition, Washington, D.C.
Dr. Nathan A. Ledeboer, PhD, D(ABMM) 

Nathan A Ledeboer is an Associate Professor of Pathology at the Medical College of Wisconsin and the Medical Director of Microbiology and Molecular Diagnostics for Wisconsin Diagnostic Laboratories and Froedtert Health.  His research endeavors, particularly in the area developing diagnostic tools for infectious diseases, have led to more than 70 publications in peer-reviewed journals and more than 100 funded research projects.
Dr. Ledeboer is also a senior editor for the Journal of Clinical Microbiology.

 

Dr. Whitney R. Buckel, PharmD, BCPS
Infectious Diseases/Antimicrobial Stewardship Clinical Pharmacist Intermountain Medical Center    Dr. Whitney Buckel is the Infectious Diseases/Antimicrobial Stewardship Clinical Pharmacist for Intermountain Medical Center, in Murray, Utah. She also serves as the co-chair of the Intermountain System-wide Antimicrobial Stewardship Committee, overseeing stewardship efforts across 22 hospitals. Whitney graduated from Purdue University College of Pharmacy in 2010, and completed a PGY-1 Pharmacy Practice and PGY-2 Infectious Diseases residency at The Johns Hopkins Hospital. Her research interest is in the design, implementation and outcomes of antimicrobial stewardship initiatives.

 

Dr. Steven Cagas, Ph.D.

Dr. Steven Cagas is a Scientific Affairs Manager within Medical and Scientific Affairs within the Molecular Diagnostics Division of Roche Diagnostics Corporation.  He has 5 years of industry experience at Roche.  He directly interfaces with clinicians and key opinion leaders to assist in the commercialization of products within the Roche Molecular Diagnostics portfolio.  He has spoken at several internal and external conferences as an invited speaker on various topics related to his areas of expertise.  Dr. Cagas received his Ph.D. in Microbiology and Molecular Genetics from the University of Medicine and Dentistry of New Jersey (currently Rutgers University).  His Ph.D. work focused on the study of the proteins expressed in the pathogenic fungus Aspergillus fumigatus.  He used a novel approach to identify the proteins expressed at various stages of development as well as in response to an antifungal agent with both studies leading to high impact publications.

 

♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦

C. diff. Spores and More ™“ Global Broadcasting Network spotlights world renowned topic experts, research scientists, healthcare professionals, organization representatives,C. diff. survivors, board members, and C Diff Foundation volunteers who are all creating positive changes in the C. diff. community worldwide.

Through their interviews, the C Diff Foundation mission will connect, educate, and empower many worldwide.

Questions received through the show page portal will be reviewed and addressed  by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP,  Dr. Fred Zar is a Professor of Clinical Medicine, Vice HeZarPhotoWebsiteTop (2)ad for Education in the Department of Medicine, and Program Director of the Internal Medicine Residency at the University of Illinois at Chicago.  Over the last two decades he has been a pioneer in the study of the treatment of
Clostridium difficile disease and the need to stratify patients by disease severity.

To access the C. diff. Spores and More program page and library, please click on the following link:    www.voiceamerica.com/show/2441/c-diff-spores-and-more

 

Take our show on the go…………..download a mobile app today

http://www.voiceamerica.com/company/mobileapps

Programming for C. diff. Spores and More ™  is made possible through our official  Sponsor;  Clorox Healthcare

CloroxHealthcare_72

C. diff. Spores and More Discuss Rebiotix: The Leader In Unlocking the Benefits of Microbiota Restoration Therapy (MRT) With Founder and CEO, Lee Jones

Listen To The May 31, 2016 PodCast

cdiffRadioLogoMarch2015
To access the live broadcast and Podcast Library
C. diff. Spores and More  Global Broadcasting Network
please click on the logo above *

C. diff. Spores and More,” Global Broadcasting Network – innovative and educational interactive healthcare talk radio program discusses

This Episode:       Rebiotix: The Leader in Unlocking the Benefits of Microbiota  Restoration Therapy (MRT)  “

With Our Guest:              Lee Jones, Founder and CEO, Rebiotix

Join us today on C. diff. Spores and More discuss Rebiotix
with Rebiotix Founder, CEO Lee Jones.  Listen in as we learn more about
the History, Company profile, the problems they are solving, and product information.  Lee will explain What is the microbiome? Their first product RBX 2660 – addressing C. diff, with the Rebiotix platform called MRT (Microbiota Restoration Therapy) and how  MRT is different
and much more.  

MORE ABOUT OUR GUEST:

Lee Jones, CEO and Founder of Rebiotix Inc., is an experienced medical technology executive and serial entrepreneur. With deep experience in the medical devices industry and in managing and advising academic scientists on commercialization efforts, Rebiotix marks her first foray into biotechnology. She is leading a fast-paced effort to develop a new way of treating disease through Microbiota Restoration Therapy (MRT). The company’s first MRT is a biologic drug targeted at recurrent Clostridium difficile infection.
Rebiotix Founder, President, CEO,  Privately held biotechnology company founded in 2011   Developing a new category of drugs to harness the human microbiome to treat disease; involves transplantation of live human-derived microbes; first target is recurrent Clostridium difficile infection, Led pioneering work with the US Food and Drug Administration to develop a new classification for the product – RBX2660 – completed Phase 2 clinical testing.

♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦

C. diff. Spores and More ™“ Global Broadcasting Network spotlights world renowned topic experts, research scientists, healthcare professionals, organization representatives,C. diff. survivors, board members, and C Diff Foundation volunteers who are all creating positive changes in the C. diff. community worldwide.

Through their interviews, the C Diff Foundation mission will connect, educate, and empower many worldwide.

Questions received through the show page portal will be reviewed and addressed  by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP,  Dr. Fred Zar is a Professor of Clinical Medicine, Vice HeZarPhotoWebsiteTop (2)ad for Education in the Department of Medicine, and Program Director of the Internal Medicine Residency at the University of Illinois at Chicago.  Over the last two decades he has been a pioneer in the study of the treatment of
Clostridium difficile disease and the need to stratify patients by disease severity.

To access the C. diff. Spores and More program page and library, please click on the following link:    www.voiceamerica.com/show/2441/c-diff-spores-and-more

Take our show on the go…………..download a mobile app today

http://www.voiceamerica.com/company/mobileapps

Programming for C. diff. Spores and More ™  is made possible through our official  Sponsor;  Clorox Healthcare

CloroxHealthcare_72